AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02787707
Drug: Persumac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour
Trial: NCT02787707
Drug: lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.7 grams Lactose every 8 hour
Trial: NCT02067884
Drug: Definity, (Lipid Microspheres) Intravenous Suspension
RxNorm normalized name: Definity, (lipid microspheres) intravenous suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive contrast agent by intravenous administration
Trial: NCT00995501
Drug: anesthesia management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light anesthesia to maintain BIS about 55
Trial: NCT04590586
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.
Trial: NCT02007434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphate buffered saline placebo for injection
Trial: NCT02007434
Drug: Lidocaine / Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
Trial: NCT02007434
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
Trial: NCT00855062
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg capsule every 12 hours by mouth
Trial: NCT00855062
Drug: minocycline placebo capsule
RxNorm normalized name: minocycline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule every 12 hours by mouth
Trial: NCT01013610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose
Trial: NCT00929162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo for ZD4054 10 mg
Trial: NCT01355458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied topically once daily
Trial: NCT01320332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT00868465
Drug: Artemether-Lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h \[+/-90 min\] after the initiation of treatment). AL is currently the first line treatment in Tanzania
Trial: NCT01376323
Drug: GSK256073 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK256073 1mg capsule
Trial: NCT01376323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule
Trial: NCT03406546
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil was used to prevent cough induced by bronchoscopy.
Trial: NCT01135017
Drug: Placebo (for Dronedarone)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)
Trial: NCT01694732
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01269996
Drug: Janumet, Lantus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection.
Trial: NCT01155154
Drug: clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
Trial: NCT01155154
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules every 6 hours for 7 days
Trial: NCT01475851
Drug: GSK548470 300 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blue tablets containing 300 mg of tenofovir disoproxil fumarate
Trial: NCT00002641
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002641
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01242202
Drug: alpha glucosidase inhibitor
RxNorm normalized name: Alpha glucosidase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01497522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo of vildagliptin 50 mg twice daily
Trial: NCT02110901
Drug: PRT-201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02110901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01744379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00637000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
Trial: NCT01290679
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
Trial: NCT04681911
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine, 1000 mg/m2, d1-d14, 3-week cycle
Trial: NCT00623740
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
Trial: NCT03098199
Drug: 150IU Menopur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \<1.5 AMH group
Trial: NCT03098199
Drug: 225IU Gonal-F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6-2.5 AMH group
Trial: NCT03098199
Drug: 75IU Menopur
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6-2.5 AMH group 2.6-6.9 AMH group \>7.0 AMH group
Trial: NCT03467932
Drug: Cohort A: ORMD-0801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 In the first two weeks of active treatment (Part 1) subjects will receive double-blind therapy according to their randomized regimen (placebo or ORMD-0801) to be taken QHS, BID or TID. Subjects will undergo a step-wise dose escalation from a starting dose of 16 mg (Visit 3), to 24 mg (Visit 4), to a top dose of 32 mg (Visit 5 onward). Subjects will then enter Part 2.~Part 2:~During Part 2, subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia.
Trial: NCT03467932
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo provided QHS, BID, TID
Trial: NCT03098199
Drug: 150IU Gonal-F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.6-6.9 AMH group
Trial: NCT03098199
Drug: 75IU Gonal-F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \>7.0 AMH group
Trial: NCT03467932
Drug: Cohort B: ORMD-0801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 In the first two weeks of active treatment, subjects will receive double-blind therapy according to their randomized regimen (ORMD 0801 8 mg or 16 mg, or matched placebo) to be taken QHS or BID. Subjects will then enter Part 2 at the same dose and regimen administered in Part 1.~Part 2 Subjects will remain on fixed doses of ORMD-0801 (or matched placebo) for 10 weeks. Doses will not be adjusted unless clinically indicated for adverse events or hypoglycemia.
Trial: NCT03804710
Drug: Developmental moisturizing cream 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will topically apply developmental moisturizing cream 1
Trial: NCT03804710
Drug: Developmental moisturizing cream 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will topically apply developmental moisturizing cream 2
Trial: NCT02557581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02614742
Drug: SFX-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An intervention releasing sulforaphane.
Trial: NCT03036865
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administered IV or SC
Trial: NCT01661972
Drug: Capecitabine and aflibercept
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.~Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.~Both agents will be administered on a 21-day cycle.
Trial: NCT00667732
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mcg twice a day, increased to 10mcg twice a day for 24 weeks
Trial: NCT01094106
Drug: NaCl 0,9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative wound infusion 2 ml/h/48h
Trial: NCT01292551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
Trial: NCT01602406
Drug: LJM716
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LJM716
Trial: NCT02034708
Drug: Dotarem®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
Trial: NCT02034708
Drug: Gadovist®/Gadavist®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
Trial: NCT00543595
Drug: MK0916
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04392063
Drug: Melatonin 3 mg
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The children received crushed Melatonin 3-mg tablets daily, 30-minutes before bedtime for 3-months.
Trial: NCT03831321
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg of diclofenac sodium will be administered to intervention group one hour before cystoscopy and lubricant gel with lidocaine will be administered to all patients just before cystoscopy.
Trial: NCT03831321
Drug: Lubricant Gel
RxNorm normalized name: Surgilube Lubricant Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To prevent patients from side effects of cystoscopy ( like urethral strictures and discomfort)
Trial: NCT02725372
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hrfor two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period
Trial: NCT00529490
Drug: Hypertonic lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
Trial: NCT00529490
Drug: Ringer's lactate
RxNorm normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
Trial: NCT01774864
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01746095
Drug: Placebo inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03315143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
Trial: NCT00181571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
Trial: NCT00335452
Drug: acetylsalicyclic acid (ASA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT03554174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microcrystalline cellulose capsule
Trial: NCT02749994
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02748135
Drug: TB-403 20mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bi-weekly intravenous doses of TB-403 20mg/kg
Trial: NCT02748135
Drug: TB-403 50mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bi-weekly intravenous doses of TB-403 50mg/kg
Trial: NCT02748135
Drug: TB-403 100mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bi-weekly intravenous doses of TB-403 100mg/kg
Trial: NCT02748135
Drug: TB-403 175mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bi-weekly intravenous doses of TB-403 175mg/kg
Trial: NCT01089322
Drug: inhaled corticosteroid plus LABA plus oral corticosteroid
RxNorm normalized name: Duramist Plus Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
Trial: NCT01167881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 10773
Trial: NCT01167881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching Glimepiride
Trial: NCT01774747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
Trial: NCT02552667
Drug: HCP1102+HGP0711Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of HCP1102 with HGP0711 Placebo for 4-week
Trial: NCT00337272
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo taken 30 minutes before bedtime days 1-28 of treatment period
Trial: NCT02552667
Drug: HCP1102Placebo+HGP0711
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of HCP1102 Placebo with HGP0711 for 4-week
Trial: NCT00039351
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00392938
Drug: antiandrogen therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02435368
Drug: mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
Trial: NCT01548430
Drug: TTP4000
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01548430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005584
Drug: ABVD regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005584
Drug: BEACOPP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00936832
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00936832
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00936832
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03859414
Drug: Therapeutic Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 5993 100/6/12.5 µg pMDI, fixed combination of BDP 100 µg + FF 6 µg + GB 12.5 µg.
Trial: NCT03859414
Drug: Therapeutic Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
Trial: NCT03859414
Drug: Supra-therapeutic Dose
RxNorm normalized name: Supra Sulfa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 5993 200/6/12.5 µg pMDI, fixed combination of BDP 200 µg + FF 6 µg + GB 12.5 µg.
Trial: NCT03859414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF 5993 placebo pMDI
Trial: NCT04194203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to atezolizumab will be administered by IV infusion at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.
Trial: NCT00518206
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (300 mg/m\^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
Trial: NCT05570643
Drug: LPS
RxNorm normalized name: ALPS LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a non-investigational product. LPS is used as challenge agent to achieve a controlled inflammatory state.
Trial: NCT05570643
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of NaCl 0.9%.
Trial: NCT01902810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo by mouth given daily throughout hospitalization
Trial: NCT01510795
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
Trial: NCT01730027
Drug: ADC3680
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
Trial: NCT01730027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
Trial: NCT01181726
Drug: Estradiol/Norethindrone acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/0.5 mg Tablets
Trial: NCT01923298
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02807298
Drug: 2% Lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
Trial: NCT02807298
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
Trial: NCT01620788
Drug: Indapamide / Losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
Trial: NCT01620788
Drug: Indapamide / Losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
Trial: NCT01620788
Drug: Hyzaar®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of Hyzaar®, oral, a day
Trial: NCT04304482
Drug: Placebo oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid oral solution
Trial: NCT00470483
Drug: Placebo treatment during 8 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator
Trial: NCT02208284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
Trial: NCT01868061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Trial: NCT00834379
Drug: pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg Tablet
Trial: NCT00941499
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 by vein on Days 1 and 2 of each 21 day cycle.
Trial: NCT02556073
Drug: usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
Trial: NCT01947114
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01128322
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02358096
Drug: ASP8232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT02358096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule